The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Oct 2014
Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.
Intensive diabetes treatment reduces the risk of developing albuminuria in individuals with type 1 diabetes. Effects on the long-term clinical course of kidney disease remain to be defined. We aimed to compare the long-term effects of intensive versus conventional treatment on incident albuminuria. ⋯ National Institute of Diabetes and Digestive and Kidney Disease.
-
Lancet Diabetes Endocrinol · Sep 2014
Meta AnalysisAssociation of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study.
Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure and hypertension risk, but whether this association is causal is unknown. We used a mendelian randomisation approach to test whether 25(OH)D concentration is causally associated with blood pressure and hypertension risk. ⋯ British Heart Foundation, UK Medical Research Council, and Academy of Finland.
-
Lancet Diabetes Endocrinol · Sep 2014
Randomized Controlled Trial Multicenter StudyHome use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
Closed-loop insulin delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia. We aimed to assess whether overnight home use of automated closed-loop insulin delivery would improve glucose control. ⋯ Diabetes UK.
-
Lancet Diabetes Endocrinol · Sep 2014
Randomized Controlled Trial Comparative StudyComparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on the optimum second-line pharmacotherapy. We compared the efficacy and safety of the sodium glucose cotransporter 2 inhibitor empagliflozin and the sulfonylurea glimepiride as add-on to metformin in patients with type 2 diabetes. ⋯ Boehringer Ingelheim and Eli Lilly.